The future of obesity treatment isn’t just about weight loss; it’s about the quality and durability of that loss. 17th of November, Atrogi will be at the London Life Sciences Week and the LSX Investival Showcase and will be represented by Dr. Hamza Bokhari to discuss how we are leading this new paradigm.
Atrogi is now a Phase 2-ready company with a differentiated platform of oral beta-2 agonists. While the field has made incredible strides, the challenges of muscle loss and weight regain remain. Our lead asset is designed to solve this. It is a foundational oral therapy that delivers high-quality, muscle-preserving weight loss, both as a standalone treatment and as a crucial add-on to any potent appetite suppressant.
Furthermore, our platform’s focus on muscle biology is highly translatable. We believe this creates a significant opportunity to address other diseases where muscle wasting is a core problem, including high-value rare disease indications.
We are keen to connect with investors and potential pharma partners who share our vision for defining the next generation of metabolic and muscular health. Please contact us to schedule a meeting.